Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma.
ERJ Open Res
; 9(5)2023 Sep.
Article
in En
| MEDLINE
| ID: mdl-37859672
ABSTRACT
Background:
The phase 3 QUEST (NCT02414854) and TRAVERSE (NCT02134028) studies demonstrated the efficacy of dupilumab 200/300â mg versus placebo every 2â weeks for 52â weeks (QUEST) and dupilumab 300â mg up to an additional 96â weeks (TRAVERSE) in patients ≥12â years of age with uncontrolled, moderate-to-severe asthma. Overall, safety was consistent with the known dupilumab safety profile. This post hoc analysis assessed long-term dupilumab efficacy for up to 3â years by exacerbation history. Patients andmethods:
Unadjusted annualised severe exacerbation rates (AER) and change from parent study baseline (PSBL) in pre-bronchodilator forced expiratory volume in 1â s (FEV1) and 5-item Asthma Control Questionnaire (ACQ-5) score were assessed in patients with PSBL eosinophils ≥150â cells·µL-1 or fractional exhaled nitric oxide ≥20â ppb and 1 (n=624), 2 (n=344), or ≥3 (n=311) exacerbations in the year before enrolment in QUEST.Results:
In all three groups, dupilumab treatment progressively reduced AER range to 0.17-0.30 during TRAVERSE (Weeks 48-96), increased pre-bronchodilator FEV1 range by 0.28-0.49â L by Week 96 and improved asthma control (reduced ACQ-5 score range by 1.51-2.03 by Week 48). For patients who first received dupilumab upon TRAVERSE enrolment, AER decreased, and lung function and asthma control improved rapidly, as was observed upon initiation of dupilumab in QUEST. Dupilumab was efficacious regardless of exacerbation history.Conclusion:
For patients with uncontrolled, moderate-to-severe asthma with elevation of at least one type 2 biomarker, dupilumab treatment provides sustained, long-term reduction of exacerbation rates and improvements in lung function and asthma control irrespective of exacerbation history.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
ERJ Open Res
Year:
2023
Document type:
Article
Affiliation country:
Estados Unidos